BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Role of adipose tissue lipolysis and adipose triglyceride lipase i
 n non-alcoholic fatty liver disease progression
DTSTART:20140410T103000
DTEND:20140410T113000
DTSTAMP:20260916T044020Z
UID:54a80f2440baea57e24ba7e5b21be8285c543366004c6271d39d5265
CATEGORIES:Conferences - Seminars
DESCRIPTION:Dr. Pooja JHA\, Medical University of Vienna and Medical Unive
 rsity of Graz (AT)\nSEMINAR of the LAUSANNE INTEGRATIVE METABOLISM and NUT
 RITION ALLIANCE (LIMNA)\nMechanisms underlying the pathogenesis of NAFLD a
 nd its progression to steatohepatitis (NASH) are poorly understood. Increa
 sed fatty acid (FA) flux from adipose tissue to the liver and impaired FA 
 signaling in liver may be involved. Since ATGL is a key intracellular lipa
 se involved in hydrolysis of stored fat and lipid partitioning\, we aimed 
 to explore the role of ATGL in mouse models of NAFLD and NASH.\nUsing meth
 ionine-choline-deficient (MCD) diet to induce NASH in ob/ob mice we showed
  that (i) increased ATGL and hormone-sensitive lipase (HSL) activity in ad
 ipose tissue and (ii) decreased ATGL activity in liver mediate loss of adi
 pose tissue followed by hepatic steatosis and inflammation. We next used m
 ice deficient in ATGL and HSL to induce steatohepatitis and endotoxemia. I
 n both these models\, we showed that ATGL plays an antiinflammatory role i
 n liver via activation of PPARα. We found that ATGL also plays an importa
 nt role in circadian regulation of hepatic lipid metabolism\, in particula
 r at zeitgeber time (ZT)12 when PPARα expression is at its peak in liver.
  In support of this hypothesis\, we found that FA profile of PPARα ligand
 s were attenuated in ATGL-KO mice at this timepoint. Our findings fuel opt
 imism that ATGL could represent an exciting therapeutic target for metabol
 ic and inflammatory liver diseases.\nBio: Dr. Jha is a Postdoctoral Fellow
  at the Hans Popper Laboratory of Molecular Hepatology\, Division of Gastr
 oenterology and Hepatology\, Department of Internal Medicine III\, Medical
  University of Vienna\, Austria\, and at the Institute of Pathology\, Medi
 cal University of Graz\, Austria
LOCATION:AI 1153 https://plan.epfl.ch/?room==AI%201153
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR